The drug behind Mounjaro and Zepbound held back tumor growth in mouse studies. It's early animal work, but obesity is tied to higher breast cancer risk.
Recap by typeshit. Post by Facebook on Facebook.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Employers can fund weight loss drugs at a fixed cap instead of open-ended coverage. Large employer coverage fell from 72% to 60% this year, per one survey.
MedPage's endocrinology roundup also has petrelintide phase II weight loss of up to 9.2% and over 100,000 new oral Wegovy scripts in two months.
Loading…